Beyond the Periodic Table’s Edge: Scientists Unravel New Chemistry for Heavy Elements
Heavy ligands such as polyoxometalates are opening a new frontier in actinide chemistry. Studying materials that are both ...
Biologists Decode the Sugar Shield That Lets Cells Glide
Proteins in the sheath of cellular protrusions control how effectively cells can adhere to surfaces. Biological cells often ...
Novel class of zwitterionic phospholipids enhances mRNA delivery
A new study conducted by researchers at Hokkaido University has unveiled a novel class of zwitterionic phospholipids capable ...
STAT3d
AbbVie, J&J to add proprietary data to AI protein model in bid to accelerate drug discovery
Imagine standing on a vast, dark plain. Without light, you cannot see dips and rolls in the grass or make out hills and ...
C&EN12d
Mandimycin: A polyene antifungal with a unique mode of action
Mandimycin is structurally similar to the last-line-of-defense antifungal amphotericin B, another glycosylated polyene ...
WNCT13d
Patient dies following muscular dystrophy gene therapy, Sarepta reports
But the company said the “severity” of the patient’s case had not previously been seen with the therapy, called Elevidys. It’s the first known patient death with the therapy, which has ...
Seeking Alpha13d
Sarepta: Disclosure Of An Elevidys Patient's Death Creates Market Uncertainty
Sarepta Therapeutics stock dropped over 20% after a patient treated with Elevidys for DMD died from acute liver failure, raising safety concerns. Despite the incident, Sarepta maintains that the ...
Seeking Alpha14d
Sarepta plunges after death linked to Elevidys (update)
Gene therapy developer Sarepta Therapeutics (NASDAQ:SRPT) lost ~20% on Tuesday to reach a new 52-week low after the company disclosed the death of a patient treated with Elevidys, its FDA-approved ...